Davern Capital Partners, LP: IONIS PHARMACEUTICALS INC (IONS): Quarterly 13F Position History
As of Q1 2026, Davern Capital Partners, LP reported 386,903 shares of IONIS PHARMACEUTICALS INC (IONS), worth $29.1M and representing 8.0% of its 13F equity book. Quarter-over-quarter share count change: + 148,426 (+62.2%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.
- 386,903Shares Held (Latest Filing)
- $29.1MReported Market Value (Latest Filing)
- 8.0%Portfolio Weight (% of 13F Equity Book)
- +148,426Quarter-over-Quarter Share Change
- +$10.2MQuarter-over-Quarter Value Change
- 386,903Peak Reported Shares (Historical)
Recent initiation: Davern Capital Partners, LP first reported IONS on the Q4 2025 filing — fewer than three quarters of history are available.
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 386,903 | +148,426 | +62.2% | $29.1M | 8.0% | $75.1 |
| Q4 2025 | 238,477 | — | — | $18.9M | 6.1% | $79.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Davern Capital Partners, LP first disclose a IONS position in 13F-HR filings?
Davern Capital Partners, LP first reported IONIS PHARMACEUTICALS INC (IONS) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.
What was Davern Capital Partners, LP's most recent quarter-over-quarter share-count change in IONS?
Between Q4 2025 and Q1 2026, Davern Capital Partners, LP added 148,426 shares of IONS (+62.2%), bringing the total reported position to 386,903 shares at a market value of $29.1M.
Does the implied price-per-share represent Davern Capital Partners, LP's cost basis in IONS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.